The Treatment Roadmap for Squamous NSCLC

  • An Independent Satellite Symposium at the European Lung Cancer Conference (ELCC)
    Geneva, 16th April 2015
    This event was accredited by EACCME®

     

    Topics Covered:

    • Where are we now (and how did we get here)?
      Nicholas Thatcher
    • Signposts to better therapy
      Jean-Charles Soria
    • Current route and future directions
      Enriqueta Felip

     

    Click on the image to open the highlights report


    Accreditation

    The ‘The Treatment Roadmap for Squamous NSCLC’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

    The ‘The Treatment Roadmap for Squamous NSCLC’ is designated for a maximum of (or ‘for up to’) 1 hour of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

    Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

    Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.


    Testimonials

    “Superb meeting – thank you!”
    Symposium attendee

    “Good venue and audio visual set up. Excellent speakers who kept to time. Faculty participation and audience voting was good due to excellent chairwoman. I was happily surprised by the turnout.”
    Nicholas Thatcher, Professor of Oncology, University of Manchester, UK

  • Message from the Chair

    Welcome to Geneva and thank you for attending this satellite symposium ‘The Treatment Roadmap for Squamous NSCLC’ at the European Lung Cancer conference, which we hope you will find engaging and informative.

    Geneva is home to some world-renowned scientific centres including CERN, where the Higgs boson was identified in March 2013, and the World Health Organisation (WHO), which was founded over 65 years ago. The latter has recently issued the following statement: “WHO is reforming to be better equipped to address the increasingly complex challenges of the health of populations in the 21st century“.

    As healthcare professionals we should consider just how much this statement resonates in our field too. The lung cancer landscape is continually evolving. Several new treatment strategies have been developed based on our better understanding of the complexities of the disease process. The molecular characterisation of NSCLC has opened many new avenues for targeted therapy, however the majority are for non-squamous advanced NSCLC. While immunotherapy – the other paramount progress in our way to perceive lung cancer management – will continue to be developed in all histological subtypes, we have decided to focus this satellite symposium on the advances to date and to come in the minority subset of squamous NSCLC.

    During this session, our expert Faculty will guide us through the latest developments in squamous NSCLC. They will provide their insights into how we can use our biological knowledge not only on how to improve treatment pathways, but also on how to maximise treatment outcomes by understanding approaches.

    We hope that you find this symposium educational and that it will further your understanding of this evolving field, providing advice to facilitate decision making in your clinical practice.

  • Programme

    Welcome and opening address
    Solange Peters

    Where are we now (and how did we get here)?
    Nicholas Thatcher

    Signposts to better therapy
    Jean-Charles Soria

    Current route and future directions
    Enriqueta Felip

    Panel discussion
    Faculty